A detailed history of Shelton Capital Management transactions in Alkermes Plc. stock. As of the latest transaction made, Shelton Capital Management holds 7,666 shares of ALKS stock, worth $222,467. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,666
Holding current value
$222,467
% of portfolio
0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.01 - $28.55 $176,394 - $218,864
7,666 New
7,666 $214,000
Q1 2024

May 15, 2024

BUY
$26.4 - $32.56 $198,528 - $244,851
7,520 New
7,520 $203,000
Q4 2023

Feb 14, 2024

BUY
$23.37 - $28.68 $188,852 - $231,763
8,081 New
8,081 $224,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.77B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Shelton Capital Management Portfolio

Follow Shelton Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.